Twist Bioscience Corporation (NASDAQ:TWST) Q1 2026 Earnings Call Transcript February 2, 2026 Twist Bioscience Corporation ...

DNA microarrays, comprising spotted PCR products of 0.6 Kb or above, have become a major platform for functional genomics. It is considered that array performance could be improved by turning to ...

Twist Bioscience Corporation Q1 2026 revenue rose 17% and guidance increased. Click for this updated look at TWST stock ...

Since the dawn of the computer age, researchers have wrestled with two persistent challenges: how to store ever-increasing ...

Gene therapy holds the promise of preventing and curing disease by manipulating gene expression within a patient's cells. However, to be effective, the new gene must make it into a cell's nucleus. The ...

Views regarding the MIAME requirements range from a perception that they are insufficient 5, to opinions that any requirements to annotate public microarray data should be abandoned. One problem with ...

Synthetic Oligonucleotides are set for rapid expansion in healthcare, food production, and data storage. The technology, vital in both existing and new markets, promises vast growth potential often ...

Gene therapy holds the promise of preventing and curing disease by manipulating gene expression within a patient's cells. However, to be effective, the new gene must make it into a cell's nucleus. The ...

When scientists sequence tumor DNA, they typically find small amounts of genetic code from bacteria, viruses and fungi—microorganisms that—if actually present in tumor tissues—could influence how they ...

Particle therapy, including proton and carbon ion radiotherapy, represents a major advancement in cancer treatment due to its ...